EvoPAR‑Prostate05 Phase 3 Trial: Saruparib Maintenance for Metastatic Hormone‑Sensitive Prostate Cancer

/in , , /by

EvoPAR‑Prostate05 is a Phase 3 maintenance trial testing the PARP1‑selective inhibitor saruparib (AZD5305) in men with metastatic hormone‑sensitive prostate cancer (mHSPC). The trial enrolls both HRR‑mutated and non‑HRR‑mutated patients but requires that each participant has confirmed homologous recombination repair mutation status (HRRm – genes such as BRCA1, BRCA2, ATM, PALB2, CDK12, RAD51B/C/D, or BARD1), homologous […]

Read more

Rinzimetostat and Darolutamide: Himalayas-1 Phase 3 Clinical Trial

/in , , /by

Himalayas‑1 is a newly initiated global Phase 3 registrational trial testing rinzimetostat (ORIC-944) in combination with darolutamide in men with metastatic castration‑resistant prostate cancer (mCRPC) who have previously been treated with abiraterone. The trial is designed as a pivotal study intended to support approval if the results are positive, with about 600 patients planned across […]

Read more

Phase 3 Trial: Metformin in Men Receiving ADT for Prostate Cancer

/in , , /by

Metformin may help blunt some of the harmful hormonal and metabolic changes caused by androgen deprivation therapy (ADT) in men with prostate cancer, according to a correlative analysis from the PRIME phase III randomized trial. ADT is a standard treatment for locally advanced and metastatic prostate cancer, but it is also associated with metabolic syndrome, […]

Read more

Confirmed Efficacy of Rucaparib in BRCA-Mutated mCRPC

/in , , /by

Rucaparib continues to strengthen its position in BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), an advanced form of prostate cancer that progresses despite hormonal therapy, with TRITON3 trial confirming not only its efficacy but also a predictable and manageable safety profile. In this phase 3 study of chemotherapy-naïve patients progressing after one prior androgen receptor pathway […]

Read more

VECTRA-01 Phase 3 Trial Tests Alpha-Emitting AZD2265 in PSMA-Positive mCRPC

/in , , /by

A pivotal Phase 3 trial called VECTRA-01 has launched to evaluate AZD2265 (²²⁵Ac-PSMA-I&T), an alpha-emitting radioligand therapy targeting PSMA-positive metastatic castration-resistant prostate cancer. The study began in May 2026, enrolling approximately 670 participants across 90 global sites, with recruitment currently active at select locations. The trial’s primary objective is to demonstrate superiority over standard of […]

Read more

Phase 3 CaBRA Trial: Adding Carboplatin for mHSPC With BRCA Mutations or Neuroendocrine Phenotype

/in , , /by

In the phase 3 CaBRA trial, carboplatin is added to the docetaxel-based chemotherapy backbone used with lifelong ADT (androgen deprivation therapy) and darolutamide,  creating a quadruple-intensification  therapy for a small but very high-risk subgroup of metastatic castration-sensitive prostate cancer. The trial focuses on tumors with either BRCA alterations or neuroendocrine differentiation, two features that are […]

Read more

Phase 3 PSMAddition Trial Reports Positive Outcomes for mHSPC

/in , , /by

Results from the PSMAddition trial were published in a phase 3 setting and showed several clear numbers worth noting. The trial compared standard double hormone-based treatment alone (ADT + ARPI) versus the same treatment plus a PSMA-targeted radioligand therapy (Pluvicto), in men with metastatic hormone-sensitive prostate cancer.The biggest headline was a 58% lower risk of […]

Read more

Deutenzalutamide in mCRPC: Meaningful Benefit in the HC‑1119‑04 Trial

/in , , /by

Nature reports the results of the HC‑1119‑04 trial, a randomized, multicenter, double‑blind, placebo‑controlled phase 3 study of deutenzalutamide (HC‑1119) in metastatic castration‑resistant prostate cancer (mCRPC) after treatment with abiraterone and docetaxel. The trial was conducted in China and enrolled 417 patients, with 276 randomized to deutenzalutamide 80 mg once daily and 141 to placebo. All […]

Read more

The ENHANCE Phase 3 Trial Tries to Cuts Hormone Therapy Side Effects

/in , , /by

Hormone therapy has been a cornerstone for treating advanced prostate cancer, starving tumors of the male hormones they crave to grow. But it often brings harsh side effects like crushing fatigue, hot flashes, high blood pressure, and loss of muscle mass that make daily life a struggle for many men. Now, a major new UK […]

Read more

Capivasertib + Abiraterone in CAPItello-281: Promising rPFS in PTEN-Deficient mHSPC

/in , , /by

The phase 3 trial CAPItello-281, has delivered compelling evidence that capivasertib combined with abiraterone could transform treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC), a subtype affecting a substantial portion of advanced cases. In this double-blind study, 1012 patients with PTEN deficiency (defined rigorously as 90% or more viable malignant cells showing no cytoplasmic staining […]

Read more